Hantavirus Infections
Also known as: HPS, Hanta virus
Methodology & AI Transparency ⓘ
Hantavirus Infections Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hantavirus pulmonary syndrome (HPS) is a rare viral infection caused by several strains of the hantavirus.
- 2 Real-world patient consensus: Synonyms for Hantavirus Infections (B37.6): HPS, Hanta virus (Infections & Antivirals).
- 3 Typical cash cost range: Workup highlights for Hantavirus Infections (B37.6): antimicrobial stewardship (narrow-spectrum in Hantavirus Infections (B37.6: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Key Infections & Antivirals biomarkers for Hantavirus Infections (B37.6): C-Reactive Protein / in Hantavirus Infections (B37.6: Procalcitonin) & Targeted PCR / in Hantavirus Infections (B37.6: Culture & Sensitivity) (Pathogen clearance / negative test (B37.6)).
Ask our AI Specialists anything about Hantavirus Infections
What Is Hantavirus Infections?
Hantavirus pulmonary syndrome (HPS) is a rare viral infection caused by several strains of the hantavirus. It is spread by mice and rats. They shed the virus in their urine, droppings, and saliva. Tiny droplets with the virus can enter the air. You can get the disease if you breathe infected air or come into contact with rodents or their urine or droppings. Most of the time, you can't get the virus from another person. But one strain of the virus found in South America, called the Andes virus, spreads through close contact with someone who has the virus.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Hantavirus Infections (B37.6, Infections & Antivirals) reflects pathogen-associated molecular pattern in Hantavirus Infections (B37.6: (PAMP) innate immune). Cross-referenced with NIH MeSH (Hantavirus Infections), longitudinal control is benchmarked via C-Reactive Protein / in Hantavirus Infections (B37.6: Procalcitonin).
Common Symptoms & Clinical Signs
- • Muscle aches, especially in the thighs, hips, and back
- • Nausea, vomiting , diarrhea or abdominal (belly) pain
- • Presentation of Hantavirus Infections (B37.6): acute fever, chills, in Hantavirus Infections (B37.6: malaise, and myalgias)
- • Secondary Hantavirus Infections clinical sign: sore throat, productive in Hantavirus Infections (B37.6: cough, sinus/ear pain,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hantavirus Infections Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B37.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: C-Reactive Protein / in Hantavirus Infections (B37.6: Procalcitonin) | Resolution to baseline (B37.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Hantavirus Infections (B37.6: Culture & Sensitivity) | Pathogen clearance / negative test (B37.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Hantavirus Infections (B37.6: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B37.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hantavirus Infections
Treatment selection for Hantavirus Infections depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hantavirus Infections)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 These findings support the use of mRNA-1083 as a multicomponent vaccine. Human vaccines & immunotherapeutics • 2026-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42213900 ↗ |
| New Insights on Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression: What a 447-Participant Study Found These results confirm that switching to once-daily DOR/3TC/TDF is a generally well-tolerated option for maintaining viral suppression in adults considering a change in therapy. Journal of acquired immune deficiency syndromes (1999) • 2021-06-01 • Phase III Randomized Trial | N = 447 | 87/100 | PMID 33633036 ↗ |
Hantavirus Infections Patient Community & “People Like Me” Threads
Filter Hantavirus Infections community threads and patient logs by age, biological sex, dosage, and treatment duration.